Europe Accelerates RevMed Drug Review; Kailera Pill Data Raises Concern

European regulators plan to accelerate their assessment of a drug developed by RevMed, according to a report from STAT News. The expedited review pathway signals a potentially faster route to market for the therapy within the European Union.

In separate developments, data for an oral GLP-1 receptor agonist from Kailera have raised concerns. The findings were noted alongside the RevMed update in a recent biotech industry roundup.

Additionally, the U.S. Food and Drug Administration has cleared an autoimmune therapy from Vera. The regulatory action marks a step forward for the company's pipeline.